Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BrainStorm Cell Therapeutics (BCLI) has received fast track status from the US Food and Drug Administration (FDA) for NurOwn to treat amyotrophic lateral sclerosis (ALS) or Lou Gehrig's disease.
Subscribe to our email newsletter
NurOwn includes autologous mesenchymal stem cells that have been induced to secrete neurotrophic factors.
The company is currently, evaluating NurOwn in a randomized, double-blind, placebo-controlled Phase II clinical trial in ALS patients.
BrainStorm chief executive officer Tony Fiorino said the status will allow them greater and more frequent dialogue with the agency as the company continues the development of this cell therapy for the treatment of ALS.
"We expect Fast Track designation, which recognizes the potential of NurOwn as to address an unmet medical need in ALS, to help speed and improve our development program," Fiorino said.
The FDA Fast Track status is designed to facilitate the development and speed up the review of drugs and biologics intended to treat serious conditions and show the potential to address unmet medical needs.